FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System

Chen Huang1,2, Dacheng Xie1,3, Jiujie Cui1,3,6, Qi Li4,5, Yong Gao4,5, and Keping Xie6

Abstract

**Purpose:** The transcription factor Forkhead box M1 (FOXM1) plays important roles in the formation of several human tumors, including pancreatic cancer. However, the molecular mechanisms by which FOXM1 promotes pancreatic tumor epithelial-to-mesenchymal transition (EMT) and metastasis are unknown.

**Experimental Design:** The effect of altered expression of FOXM1 and urokinase-type plasminogen activator receptor (uPAR) on EMT and metastasis was examined using animal models of pancreatic cancer. Also, the underlying mechanisms of altered pancreatic cancer invasion and metastasis were analyzed using *in vitro* molecular biology assays. Finally, the clinical relevance of dysregulated FOXM1/uPAR signaling was investigated using pancreatic tumor and normal pancreatic tissue specimens.

**Results:** Pancreatic tumor specimens and cell lines predominantly overexpressed the FOXM1 isoform FOXM1c. FOXM1c overexpression promoted EMT in and migration, invasion, and metastasis of pancreatic cancer cells, whereas downregulation of FOXM1 expression inhibited these processes. The level of FOXM1 expression correlated directly with that of uPAR expression in pancreatic cancer cell lines and tumor specimens. Moreover, FOXM1c overexpression upregulated uPAR expression in pancreatic cancer cells, whereas inhibition of FOXM1 expression suppressed uPAR expression. Furthermore, transfection of FOXM1c into pancreatic cancer cells directly activated the uPAR promoter, whereas inhibition of FOXM1 expression by FOXM1 siRNA suppressed its activation in these cells. Finally, we identified an FOXM1-binding site in the uPAR promoter and demonstrated that FOXM1 protein bound directly to it. Deletion mutation of this site significantly attenuated uPAR promoter activity.

**Conclusions:** Our findings demonstrated that FOXM1c contributes to pancreatic cancer development and progression by enhancing uPAR gene transcription, and thus, tumor EMT and metastasis. *Clin Cancer Res;* 20(6); 1477–88. ©2014 AACR.

Introduction

Pancreatic cancer is one of the leading causes of cancer deaths in industrialized countries, and its incidence seems to be increasing (1). Despite improvements in early diagnosis, surgical techniques, and chemotherapy, the majority of patients with pancreatic cancer die of the physiologic effects of invasion and metastasis to the regional lymph nodes and/or distant organs (2). Unfortunately, little is known concerning the reasons for the aggressiveness of and dismal prognosis for pancreatic cancer. Therefore, improved understanding of the molecular mechanisms underlying pancreatic cancer progression is an urgent need (3, 4).

Forkhead box M1 (FOXM1), previously known as HNF-3, HNF-3β, MPP2, Win, and Trident, is a transcription factor in the FOX protein superfamily containing a conserved winged helix DNA-binding domain (5). The human FOXM1 gene consists of 10 exons, two of which, exon Va (A1) and exon Vla (A2), are alternatively spliced. These splices give rise to three distinct isoforms of FOXM1: FOXM1a, FOXM1b,
Tumor cell invasion and metastasis depend on the coordinated and temporal expression of proteolytic enzymes to degrade the extracellular matrix surrounding the tumor. The tumor cell–associated urokinase-type plasminogen activator (uPA) system, which consists of the serine protease uPA, membrane-bound uPA receptor (uPAR), and uPA inhibitors plasminogen activator inhibitor (PAI)-1 and PAI-2 plays important roles in these pericellular processes (19–21). uPAR, which is a glycosyl phosphatidylinositol–anchored protein, not only is bound to the cell surface, but also has a soluble form (suPAR). Accumulating clinical and experimental evidence has demonstrated that uPAR plays a central role in angiogenesis and metastasis of many human tumors, including pancreatic cancer (22–24). Furthermore, inhibition of uPAR expression by a monoclonal antibody or siRNA has inhibited human pancreatic tumor growth, angiogenesis, and metastasis both in vitro and in vivo (25, 26). However, little is known about the molecular mechanisms underlying dysregulated expression and function of uPAR in pancreatic cancer cells.

In the present study, we sought to determine the role of the FOXM1 isoforms in pancreatic cancer EMT, invasion, and metastasis and their regulatory functions about uPAR expression and function. We discovered that pancreatic cancer cell lines had high levels of expression of FOXM1c and that FOXM1b and FOXM1c promoted EMT and metastasis of pancreatic cancer cells via transcriptional regulation of the expression of uPA and uPAR.

### Materials and Methods

Details about our study animals and experimental procedures are described in the Supplementary Materials and Methods section.

### Cell lines and culture conditions

The human pancreatic adenocarcinoma cell lines AsPC-1, CaPan-1, MiaPaca-2, BxPC-3, PAN-1, and human embryonic kidney 293 (HEK293) cells were purchased from the American Type Culture Collection (ATCC). The pancreatic cancer cell lines MDA Panc-28 and MDA Panc-48 were gifts from Dr. Paul J. Chiao (The University of Texas MD Anderson Cancer Center, Houston, TX). The human pancreatic adenocarcinoma metastasis cell line COLO357 and its fast-growing variant FG and liver-metastatic variants L3.3 and L3.7 in nude mice as well as the murine ductal adenocarcinoma cell line Panc02 and its highly metastatic variant Panc02-H7 were described previously (18). All of these cell lines were maintained in plastic flasks as adherent monolayers in Eagle minimal essential medium supplemented with 10% FBS, sodium pyruvate, nonessential amino acids, 1-glutamine, and vitamin solution (Flow Laboratories). The immortalized normal human pancreatic ductal epithelial cell line human pancreatic ductal epithelial (HPDE; provided by Dr. Tsao, Ontario Cancer Institute, Ontario, Canada) was maintained in keratinocyte serum-free medium supplemented with EGF and bovine pituitary extract (Invitrogen). The cell lines were obtained directly from ATCC that conducts cell line...
characterizations or authentication by the short tandem repeat profiling and passaged in our laboratory for less than 6 months after receipt.

Human tissue specimens and immunohistochemical analysis

Expression of FOXM1, uPAR, uPA, and PAI-1 in pancreatic cancer cells was analyzed using a human pancreatic tumor and normal pancreatic tissue microarray (TMA; US Biomax). Use of the tissue specimens was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board (Houston, TX). Standard immunohistochemical procedures were performed using anti-FOXM1 (Santa Cruz Biotechnology), anti-uPAR (American Diagnostica), anti-uPA, and anti-PAI-1 (Santa Cruz Biotechnology) antibodies. The specificities of those antibodies have been validated in prior reports (22–26). The staining results were scored by two investigators blinded to the clinical data as described previously (27, 28).

Plasmids and siRNAs

The plasmid pcDNA3.1-FOXMc and control vector pcDNA3.1 were designed previously (14). To generate pcDNA3.1-FOXMc and pcDNA3.1-FOXMc plasmids, full-length human FOXMc and FOXMc cDNA were released via EcoRI and XhoI digestion of human cytomegalovirus. FOXMc (7) and FOXMc (8) cDNA expression vectors were subcloned into pcDNA3.1. An siRNA sequence targeting FOXMc was 5'-UCCUUCUCCCUCAGAUAUAdTdT (13).

Transfection of pancreatic cancer cells

Transfection of plasmids and siRNAs into pancreatic cancer cells was performed using Lipofectamine LTX (Invitrogen) and Lipofectamine 2000 CD (Invitrogen) reagent, respectively. The cells were transfected with plasmids or siRNA at various doses as indicated for 48 hours before performance of functional assays. Pancreatic cancer cells treated with transfection reagent alone were included as mock-treated controls.

Construction of reporter plasmids and mutagenesis

A 1.103-kb fragment containing 5' uPAR sequences from −873 to +230 bp relative to the transcription initiation site was subcloned into the Asp718 and XhoI sites of the pGL3-basic vector (Promega). The resulting full-length reporter plasmid, designated puPAR1103, contained two FOXMc binding sites: ACAAACAA and TAATCA. Its deletion mutants were prepared for cotransfection with a 5'-actgctccaaagcgccgttc-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1a primers 5'-ttgaggagagtgattttgag-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1b primers 5'-caggtttaagcagcagcaga-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1c primers 5'-caggtttaagcagcagcaga-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense strand 5'-caccattgcagtaagtcgttc-3' and antisense strand 5'-aggttttgtctactggaacttc-3'. GAPDH was used as an internal control. Each PCR was run in triplicate for the target and internal control genes.

Real-time reverse transcription PCR

Total RNA was extracted from pancreatic tumor cells using TRIzol reagent (Invitrogen). Two micrograms of total RNA was then reverse transcribed using a First-Strand cDNA Synthesis Kit (Promega) to synthesize cDNA specimens. Quantitative PCR amplification of expression of the FOXMc gene in the cells was performed using 2 μL of cDNA and SYBR Green Master Mix (Bio-Rad) as recommended by the manufacturer for the FOXMc primers 5'-actgctccaaagcgccgttc-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1a primers 5'-ttgaggagagtgattttgag-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1b primers 5'-caggtttaagcagcagcaga-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1c primers 5'-caggtttaagcagcagcaga-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense strand 5'-caccattgcagtaagtcgttc-3' and antisense strand 5'-aggttttgtctactggaacttc-3'. GAPDH was used as an internal control. Each PCR was run in triplicate for the target and internal control genes.

Reverse transcription PCR

Total RNA was extracted from pancreatic tumor cells using TRIzol reagent (Invitrogen). Two micrograms of total RNA was then reverse transcribed using a First-Strand cDNA Synthesis Kit (Promega) to synthesize cDNA specimens. Quantitative PCR amplification of expression of the FOXMc gene in the cells was performed using 2 μL of cDNA and SYBR Green Master Mix (Bio-Rad) as recommended by the manufacturer for the FOXMc primers 5'-actgctccaaagcgccgttc-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1a primers 5'-ttgaggagagtgattttgag-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1b primers 5'-caggtttaagcagcagcaga-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), FOXMc1c primers 5'-caggtttaagcagcagcaga-3' (forward) and 5'-ctctctgtcagctgtaaa-3' (reverse), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense strand 5'-caccattgcagtaagtcgttc-3' and antisense strand 5'-aggttttgtctactggaacttc-3'. GAPDH was used as an internal control. Each PCR was run in triplicate for the target and internal control genes.

Chromatin immunoprecipitation assay

Pancreatic tumor cells (2 × 10⁶) were prepared for a chromatin immunoprecipitation (ChIP) assay using a ChIP assay kit (Millipore) according to the manufacturer’s protocol. The resulting immunoprecipitated DNA specimens were analyzed using PCR to amplify a 231-bp region of the uPAR promoter with the primers 5'-cagctcctgctccttcgctc-3' (sense) and 5'-ctctctgtcagctgtaaa-3' (antisense) and a 627-bp region of the uPAR promoter with the primers 5'-cagctcctgctccttcgctc-3' (sense) and 5'-cagctcctgctccttcgctc-3' (antisense). The PCR products were scored by two investigators blinded to the clinical data as described previously (27, 28).
were resolved electrophoretically on a 2% agarose gel and visualized using ethidium bromide staining.

**Statistical analysis**

The significance of the patient specimen data was determined using the Pearson correlation coefficient. The significance of the *in vitro* and *in vivo* data was determined using the Student *t* test (two tailed), Mann–Whitney test (two tailed), or one-way ANOVA. *P* values less than 0.05 were considered significant.

**Results**

**FOXM1 overexpression and its direct association with clinicopathological parameters and expression of genes related to metastasis in pancreatic cancer cells**

We first detected the expression of FOXM1 protein in pancreatic cancer cells using immunohistochemical staining with a specific anti-FOXM1 antibody in a TMA containing 70 primary pancreatic tumor and 10 normal pancreatic tissue specimens. We found FOXM1-positive staining in the nuclei and/or cytoplasm of the tumor cells and FOXM1-negative or weakly FOXM1-positive staining in the cytoplasm of normal pancreatic tissue cells adjacent to the tumor cells or normal pancreatic tissue cells (31). We then analyzed the relationship between clinicopathological parameters and FOXM1 expression in pancreatic tumor specimens. We observed a correlation between increased FOXM1 expression and decreased tumor differentiation and a significant difference in FOXM1 expression and tumor differentiation between well (grade 1) and poorly (grade 3) differentiated tumors (*P* < 0.05). In addition, FOXM1 expression was positively correlated with disease stage, indicating that FOXM1 expression was upregulated in late-stage pancreatic tumors. This association was significant for stage I and IV tumors (*P* < 0.05). Moreover, FOXM1 expression levels in lymph node and distant metastasis specimens were significantly higher than those in nonmetastasis specimens (*P* < 0.05). These results demonstrated that FOXM1 expression plays critical roles in pancreatic cancer development and progression and is a valuable biomarker for this disease.

To determine the molecular basis for the effect of altered FOXM1 expression on pancreatic cancer EMT, and metastasis, we sought to detect the expression of uPA and uPAR in the same TMA using immunohistochemical staining and quantified the staining for FOXM1, uPA, and uPAR in the pancreatic tumor specimens. We found that the levels of FOXM1, uPA, and uPAR expression were significantly higher in specimens obtained from patients with metastatic disease than in those obtained from patients without it (Fig. 1A and B). We observed immunostaining for uPA and uPAR mainly in the cytoplasm of the pancreatic cancer cells. Moreover, we observed significant direct correlations between FOXM1 and uPAR expression, between FOXM1 and uPA expression, and between uPA and uPAR expression (*P* < 0.05; Fig. 1C). However, we did not find a significant correlation between FOXM1 and PAI-1 expression (data not shown). These findings suggested that FOXM1, uPA, and uPAR expression was closely interrelated and correlated with pancreatic cancer metastasis.

**FOXM1 isoform expression in pancreatic cancer cells and tumors**

Real-time PCR analysis using pancreatic cancer, HPDE, and HEK293 cells revealed that FOXM1c is the predominant isoform in HPDE and pancreatic cancer cells, whereas FOXM1b is the predominant isoform in HEK293 cells (Fig. 2A). Moreover, expression of FOXM1c in highly metastatic L3.7 human pancreatic adenocarcinoma cells was significantly higher than that in poorly metastatic COLO357 cells (*P* < 0.05), suggesting that FOXM1c expression correlated directly with metastatic ability. We further examined the FOXM1 isoform expression in human pancreatic tumor and paired adjacent normal pancreatic tissue specimens using real-time PCR. We observed that expression of FOXM1c in the tumors was significantly higher than that in adjacent normal tissue (*P* < 0.05). These findings demonstrated that FOXM1c may be the most important FOXM1 isoform to pancreatic cancer development and progression.

To determine the roles of the FOXM1 isoforms in pancreatic cancer metastasis, we measured the expression of FOXM1, uPA, uPAR, and PAI-1 in nine pancreatic cancer cell lines and one transformed HPDE cell line (Fig. 2B). uPA and uPAR expression correlated directly with FOXM1 expression in the pancreatic cancer cell lines. Furthermore, the levels of FOXM1 and uPAR expression were higher in highly metastatic human and murine pancreatic cancer cell lines (L3.7 and Panc02-H7) than in poorly metastatic cell lines (COLO357 and Panc02), suggesting that FOXM1 and uPAR expression correlated directly with metastatic ability.

To obtain causal evidence of a direct correlation between expression of FOXM1 and that of uPA and uPAR, we sought to determine the impact of altered expression of FOXM1 on expression of uPA and uPAR in human pancreatic cancer cell lines with either low (COLO357) or high (L3.7) levels of FOXM1 expression. To that end, we transfected the FOXM1 expression vectors pcDNA3.1-FOXM1a, pcDNA3.1-FOXM1b, and pcDNA3.1-FOXM1c and the control vector pcDNA3.1 into COLO357 cells, which typically have an epithelial phenotype (18). We found that increased expression of FOXM1b or FOXM1c in COLO357 cells led to markedly increased uPA and uPAR mRNA and protein expression (Fig. 2C), and that the cells underwent morphologic changes typical of EMT in that they scattered from cell clusters and acquired a spindle-shaped and fibroblast-like phenotype. Conversely, we transfected FOXM1 siRNA (siFOXM1) or a control siRNA into L3.7 cells, which have a mesenchymal phenotype (18). This transfection greatly inhibited FOXM1 mRNA and protein expression (Fig. 2D). Also, the L3.7 cells underwent a morphologic change typical of mesenchymal-to-epithelial transition, going from an elongated, spindle-shaped, mesenchymal phenotype to a more rounded, epithelial-like phenotype. These results indicated that altered FOXM1b and FOXM1c expression...
Figure 1. Expression of FOXM1, uPAR, and uPA and its correlation with metastasis in pancreatic tumors. Staining of 70 primary pancreatic tumor specimens and 10 normal pancreatic tissue specimens for FOXM1, uPAR, and uPA protein was performed using a TMA. A, FOXM1, uPAR, and uPA expression was much higher in primary pancreatic tumor specimens obtained from patients with lymph node and/or distant metastasis [Metastasis (+)] than in those obtained from patients without metastasis [Metastasis (−)]. *P < 0.05. B, representative photos of uPA, uPAR, and FOXM1 expression in primary pancreatic tumor specimens obtained from patients with or without metastasis at a magnification of ×200 (inserts, ×400). C, positive correlation of FOXM1 expression levels with uPA and uPAR expression levels in pancreatic tumor specimens (Pearson correlation test). Note: some of the dots on the graphs represent more than one specimen (overlapping scores).
Figure 2. Expression of FOXM1a, FOXM1b, and FOXM1c and its influence on EMT in pancreatic cancer cells. A, real-time PCR analysis using specific primers for FOXM1a, FOXM1b, and FOXM1c with pancreatic cancer cell lines and tumor specimens. FOXM1c was the predominant isoform expressed in HPDE cells and all pancreatic cancer cell lines, whereas FOXM1b was the predominant isoform expressed in HEK293 cells. The expression of FOXM1c in the highly metastatic L3.7 cells was much higher than that in the poorly metastatic COLO357 cells. Also, the expression of FOXM1c in pancreatic tumor specimens was much higher than that in adjacent normal pancreatic tissue specimens. B, Western blot analysis of FOXM1, uPA, uPAR, and PAI-1 protein expression in the pancreatic cancer cell lines and HPDE cells. C, COLO357 cells were transfected with pcDNA3.1-FOXM1a (pFOXM1a), -FOXM1b (pFOXM1b), or -FOXM1c (pFOXM1c) or with pcDNA3.1 alone and incubated for 48 hours. Forced expression of FOXM1b or FOXM1c in COLO357 cells greatly increased FOXM1, uPA, and uPAR mRNA and protein expression (left). Phase-contrast photomicrographs demonstrated that COLO357 cells underwent morphologic changes typical of EMT after FOXM1b or FOXM1c overexpression (right). D, L3.7 cells were transfected with siFOXM1 or control siRNA and incubated for 48 hours. Forced siFOXM1 expression in these cells markedly inhibited FOXM1, uPA, and uPAR mRNA and protein expression (left). Phase-contrast photomicrographs demonstrated that L3.7 cells underwent morphologic changes typical of mesenchymal-to-epithelial transition after knockdown of FOXM1 expression (right).
affected the epithelial and mesenchymal phenotypes of pancreatic cancer cells.

**Effect of altered FOXM1 expression on pancreatic cancer cell migration and invasion in vitro and tumor growth and metastasis in vivo**

To determine the effect of altered FOXM1 expression on migration of pancreatic cancer cells, we transfected COLO357 and L3.7 cells with pcDNA3.1-FOXM1a, pcDNA3.1-FOXM1b, pcDNA3.1-FOXM1c, and siFOXM1 for 48 hours. We then wounded the transfected cells via scratching and maintained them at 37°C for an additional 12 hours. We observed that overexpression of FOXM1b and FOXM1c strongly promoted the flattening and spreading of COLO357 cells, whereas knockdown of expression of FOXM1 attenuated the flattening and spreading of L3.7 cells (Supplementary Fig. S1A). Also, cell migration assay results indicated that overexpression of FOXM1b and FOXM1c promoted the migratory ability of COLO357 cells, whereas knockdown of expression of FOXM1 attenuated this ability of L3.7 cells (Supplementary Fig. S1B). Similarly, overexpression of FOXM1b and FOXM1c promoted the invasiveness of COLO357 cells, whereas knockdown of expression of FOXM1 attenuated the invasiveness of L3.7 cells (Supplementary Fig. S1C).

Consistent with the impact of altered FOXM1 expression on the migration and invasion of pancreatic cancer cells in vitro, transfection of COLO357, AsPC-1, BxPC-3 and PANC-1 with pcDNA3.1-FOXM1b or pcDNA3.1-FOXM1c significantly promoted pancreatic tumor growth (Fig. 3A and B).
and increased liver metastasis of COLO357 cells \( (P < 0.05) \) in nude mice (Fig. 3C). However, transfection with siFOXM1 or siFOXM1a/c significantly inhibited pancreatic tumor growth \( (P < 0.05; \) Fig. 4A and B) and inhibited liver metastasis of L3.7 cells (Fig. 4C and D) in the mice. These findings clearly indicated that FOXM1b and FOXM1c are oncogenic and promote invasion and metastasis of pancreatic tumors.

**Transcriptional activation of uPAR expression by FOXM1 in pancreatic cancer cells**

To determine whether FOXM1 regulates uPAR expression at the transcriptional level, we analyzed the uPAR promoter sequence for the presence of potential FOXM1-binding elements by using the FOXM1 consensus sequences \( 5'-A(C/T)AAA(C/T)AA-3' \), \( 5'-AGATTGAGTA-3' \), and \( 5'-TAATCA-3' \) (29, 32, 33). We identified two putative FOXM1-binding elements (referred to as DNA sequences #1 and #2) in the uPAR promoter sequence (Fig. 5A). We then cotransfected a uPAR promoter luciferase reporter construct (puPAR1103) into COLO357 cells with pcDNA3.1-FOXM1a, pcDNA3.1-FOXM1b, pcDNA3.1-FOXM1c, or pcDNA3.1. Cotransfection with pcDNA3.1-FOXM1b or pcDNA3.1-FOXM1c activated the luciferase activity driven by the uPAR promoter (Fig. 5B). Conversely, we knocked down FOXM1 expression in L3.7 cells by cotransfecting them with siFOXM1 and the uPAR promoter. We observed that siFOXM1 inhibited the luciferase activity driven by the uPAR promoter (Fig. 5B). Furthermore, transfection with puPAR627 (lacking DNA sequence #1) attenuated the luciferase activity driven by the uPAR promoter in COLO357 and L3.7 cells (Fig. 5C).

Finally, to prove that FOXM1 is recruited to the endogenous uPAR promoter in pancreatic cancer cells during transcription in vivo, we performed ChIP assays using

![Figure 4](https://example.com/figure4.png)

**Figure 4.** Influence of knockdown of FOXM1a, FOXM1b, and FOXM1c expression on pancreatic tumor growth and metastasis. L3.7 cells were transfected with siFOXM1 or control siRNA and injected into nude mice. The tumor-bearing mice were killed when they became moribund or on day 21 after tumor-cell injection. A, tumor growth in the mice. The cells were injected subcutaneously \( (1 \times 10^6 \text{ per mouse}) \) into the right scapular region. Shown are the resulting tumor weights (left), gross tumors (middle), and resected tumors (right). \( * \), \( P < 0.01 \) in a comparison of the siFOXM1-treated group with the mock-treated and control groups. B, experiments similar to those in A were performed using AsPC-1, BxPC-3, and PANC-1 cells and siFOXM1 or FOXM1a and FOXM1c siRNA (siFOXM1a/c). Shown are representative tumors resected from mice injected with each cell type. C, pancreatic tumor metastasis in the study mice. L3.7 cells \( (1 \times 10^5 \text{ per mouse}) \) were injected into the ileocolic veins of 5 mice. Shown are the numbers of liver metastases. D, the numbers of gross liver metastases (bottom left) and hematoxylin and eosin-stained liver metastasis sections (bottom right) in the mice in C. \( * \), \( P < 0.01 \) in a comparison of the siFOXM1-treated group with the mock-treated and control groups.
chromatins prepared from COLO357 and L3.7 cells and two primer sets flanking 231-bp (–873 to –643; site #2) and 627-bp (–397 to +230; site #1) regions of the uPAR promoter. We observed that the 231-bp DNA fragment was amplified in the immunoprecipitates by anti-FOXM1 antibodies but not by a control immunoglobulin G (IgG) antibody in both cell types (Fig. 5D), suggesting that endogenous FOXM1 bound to the region from –873 to –643 bp of the uPAR promoter. In addition, induced FOXM1b or FOXM1c overexpression led to increased FOXM1 recruitment to the uPAR promoter in COLO357 cells, whereas knockdown of FOXM1 expression led to decreased FOXM1 recruitment to the uPAR promoter in L3.7 cells (Fig. 5D). Collectively, these findings demonstrated that FOXM1 bound to the region from –707 to –692 bp of the uPAR promoter and

Figure 5. Direct binding of FOXM1 to the uPAR promoter. A, sequences and positions of putative FOXM1-binding elements on the uPAR promoter puPAR1103 (sites #1 and #2) and a deletion mutation of the uPAR promoter puPAR627 (site #1). B, COLO357 cells were cotransfected with 0.8 μg of the uPAR promoter luciferase construct puPAR1103 and 0 to 0.8 μg of pcDNA3.1-FOXM1a (pFOXM1a), pcDNA3.1-FOXM1b (pFOXM1b), pcDNA3.1-FOXM1c (pFOXM1c), or pcDNA3.1-FOXM1c (pFOXM1c), or pcDNA3.1 (left), whereas L3.7 cells were cotransfected with 0.8 μg of puPAR1103 and 50 nmol/L siFOXM1 or control siRNA (siControl; right). The promoter activity in the cells was measured using a dual luciferase assay kit. *, P < 0.01. C, COLO357 and L3.7 cells were cotransfected with pGL3-basic, puPAR1103, or puPAR627. The promoter activity in the cells was assessed using a dual luciferase assay kit. D, ChIP assay. Chromatins were isolated from COLO357 cells transfected with pcDNA3.1-FOXM1a, pcDNA3.1-FOXM1b, pcDNA3.1-FOXM1c, or pcDNA3.1, and binding of FOXM1 to the uPAR promoter was analyzed using a specific anti-FOXM1 antibody and oligonucleotides flanking the uPAR promoter regions containing putative FOXM1-binding sites as described in Materials and Methods (left). Similar ChIP assays were conducted using chromatins isolated from L3.7 and L3.7-siFOXM1 cells (right). Normal IgG was used as a control, and 1% of the total cell lysates was subjected to PCR analysis before immunoprecipitation (input control).
positively regulated uPAR transcription in pancreatic cancer cells.

Discussion

In the present study, we sought to determine the critical roles of the FOXM1 isoforms in pancreatic cancer pathogenesis. We found that FOXM1b and FOXM1c transcriptionally activated the uPAR gene, constituting a novel signaling pathway that directly impacts EMT in and invasion and metastasis of pancreatic cancer cells and that alteration of these two isoforms modulates the clinicopathological behavior of pancreatic cancer. Collectively, our novel clinical and mechanistic findings strongly suggest that dysregulated FOXM1b or FOXM1c expression causes abnormal uPAR and uPA expression in pancreatic cancer cells and is a critical/an important contributor to the pathogenesis and aggressiveness of this cancer.

The transcription factor FOXM1 is a key regulator of the cell cycle at both the G1–S and G2–M phase (33). Besides its involvement in cell-cycle transition, it plays important roles in tumor angiogenesis, EMT, invasion, and metastasis (9, 10). Lines of evidence demonstrate that FOXM1 is highly expressed in human lung carcinoma (11), cervical cancer (12), gastric cancer (13), and glioblastoma (14) cells and in a number of other types of human tumor cells (34), suggesting that FOXM1 is involved in the development and progression of many different human tumors. In the present study, we found that FOXM1 was highly expressed in human pancreatic tumors and that high expression of FOXM1 was strongly correlated with histologic differentiation, by directly transactivating the c-Myc promoter via the P1 and P2 TATA boxes. Furthermore, studies demonstrated that enforced expression of FOXM1c in cervical and ovarian cancer cells enhances their proliferation, anchorage-independent growth, and migration and invasive ability (12, 40).

In the present study, we found that the role of FOXM1c predominated over those of the other two isoforms in human pancreatic cancer cells and tumors. In addition, the expression of FOXM1c in highly metastatic human pancreatic cancer cells was much higher than that in poorly metastatic cells. Moreover, FOXM1b and FOXM1c promoted EMT in and migration, invasion, and metastasis of pancreatic cancer cells by upregulating uPA and uPAR expression; FOXM1a did not have any such effects. These data demonstrate that FOXM1b and FOXM1c both play important roles in pancreatic cancer pathogenesis and progression.

Authors first described the function of the uPA system in tumor invasion and metastasis by demonstrating pivotal roles of uPA and uPAR during pericellular proteolysis in degradation of the extracellular matrix (23). In addition, via their interactions with extracellular matrix proteins as well as integrins and other transmembrane receptors, uPA and uPAR modulate tumor angiogenesis and growth by regulating the adhesion, migration, and proliferation of cancer cells and/or vascular endothelial cells (41, 42). A large body of experimental evidence from in vitro, in vivo, and clinical studies indicates critical roles for the uPA system in the development of human tumors, including pancreatic cancer (22–26). Recently, a study demonstrated that uPAR induced EMT and promoted breast cancer metastasis by activating diverse cell signaling pathways (43). Moreover, researchers observed that uPAR-initiated cell signaling could be targeted to reverse EMT in cancer cells (21). Our present findings are consistent with these previous results, as they suggest a pivotal role for the uPA system in the progression of pancreatic cancer. In addition, we proved that uPAR expression levels correlated directly with FOXM1 expression levels in pancreatic cancer cells and tumors. In addition, FOXM1b and FOXM1c increased the expression of both uPA and uPAR in pancreatic cancer cells, whereas...
knockdown of expression of FOXM1 decreased the expression of uPA and uPAR. Moreover, FOXM1 bound directly to the promoter region of the uPAR gene and positively activated its activity, demonstrating that uPAR is a novel downstream target of FOXM1. Given the important effects of uPAR on pancreatic cancer progression and the transcriptional regulation of uPAR by FOXM1, FOXM1 contributes to the pathogenesis and aggressive biology of pancreatic cancer, at least in part, by increasing uPAR expression, suggesting that dysregulated signaling by this novel FOXM1/uPAR pathway promotes pancreatic cancer development and progression.

Researchers have identified upstream signals for uPAR other than FOXM1, suggesting that the presence of transcriptional factors is essential for regulation of uPAR expression (23). For example, Sp1, a zinc finger transcription factor, promotes the expression of uPAR by binding to the uPAR promoter and subsequently affecting cell biology (44). In fact, investigators have frequently found overexpression of Sp1 in a wide variety of human tumors, including pancreatic cancer, and that Sp1 expression is correlated with aggressive biology and poor clinical outcome of cancer (45). However, whether overexpression of Sp1 contributes to pancreatic cancer progression via regulation of uPAR is unclear. Recent studies clearly demonstrated that the transcription factor hypoxia-inducible factor (HIF)-1α consistently upregulated the expression and activity of uPAR, thus contributing to the invasiveness of human cancer cells (46). Given the roles of HIF-1α in pancreatic cancer growth and metastasis (47), regulation of uPAR expression may be a mechanism whereby HIF-1α signaling affects cancer cells, leading to the development of pancreatic cancer. Thus, we are currently investigating whether HIF-1α signals promote pancreatic cancer development and progression via regulation of uPAR expression. More importantly, researchers demonstrated that transcription factors have many cross-links in tumor signal transduction and that different transcription factors can function cooperatively to activate target gene expression during tumorigenesis (48). Determination of how the interactions of FOXM1 with other transcription factors regulate the expression and function of uPAR and contribute to pancreatic carcinogenesis warrants further investigation. Therefore, further exploration of the molecular mechanisms that result in uPAR overexpression may not only shed more light on abnormal uPAR activation in pancreatic cancer cells, but also help improve understanding of the value of uPAR as a prognostic factor and aid in the development of effective pancreatic cancer therapies that target uPAR.

In summary, this study provided critical insight into the role of the FOXM1 isoforms in pancreatic cancer progression and identified a critical role for novel FOXM1/uPAR signaling in the progression of pancreatic cancer. Collectively, our results not only identify a detailed molecular mechanism underlying regulation of uPA/uPAR by FOXM1c in particular in pancreatic cancer progression, but also identify aberrant FOXM1c/uPAR signaling as a promising new molecular target for designing novel therapeutic modalities to control pancreatic cancer progression.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: K. Xie, C. Huang, D. Xie, J. Cui, Q. Li
Development of methodology: K. Xie, C. Huang, J. Cui, Q. Li, Y. Gao
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Xie, C. Huang, D. Xie, J. Cui, Q. Li, Y. Gao
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K. Xie, C. Huang, D. Xie, J. Cui, Q. Li, Y. Gao
Writing, review, and/or revision of the manuscript: K. Xie, C. Huang, D. Xie, J. Cui, Y. Gao
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Xie, C. Huang, J. Cui, Q. Li
Study supervision: K. Xie, C. Huang, J. Cui

Acknowledgments
The authors thank Don Norwood for editorial comments.

Grant Support
This work was supported in part by grants R01-CA129956, R01-CA148954, R01-CA152309, and R01-CA172233 (to K. Xie) from the NIH; grants 81101844 and 81210108027 (to C. Huang) from the National Natural Science Foundation of China; grants 2012040 and 13PI0024 (to C. Huang) from the Shanghai Municipal Human Resources and Social Security Bureau; and grant 7YQ2013092 (to C. Huang) from the Shanghai Health and Family Planning Commission.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 25, 2013; revised November 11, 2013; accepted December 8, 2013; published OnlineFirst January 22, 2014.

References

Clinical Cancer Research

FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System

Chen Huang, Dacheng Xie, Jiujie Cui, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-2311

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2015/07/17/1078-0432.CCR-13-2311.DC1

Cited articles
This article cites 48 articles, 22 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/6/1477.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/20/6/1477.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.